Editing GSK plc (section)

===2001–2010===
[[File:Andrew Witty in 2015.jpg|thumb|alt=photograph|[[Andrew Witty]], GSK's CEO from May 2008, to April 2017]]

GSK completed the acquisition of New Jersey–based [[Block Drug]] in 2001, for {{US$|1.24 billion}}.<ref>{{cite web |title=GlaxoSmithKline Completes the Purchase of Block Drug for $1.24&nbsp;Billion |url=http://www.prnewswire.com/news-releases/glaxosmithkline-completes-the-purchase-of-block-drug-for-124-billion-71032672.html |url-status=usurped |archive-url=https://web.archive.org/web/20140527213852/https://www.prnewswire.com/news-releases/glaxosmithkline-completes-the-purchase-of-block-drug-for-124-billion-71032672.html |archive-date=27 May 2014 |access-date=1 August 2010 |publisher=PR Newswire}}</ref> In 2006, GSK acquired the US-based consumer healthcare company CNS Inc., whose products included Breathe Right nasal strips and FiberChoice dietary supplements, for US$566{{nbsp}}million in cash.<ref>{{cite news |last=Stouffer |first=Rick |date=9 October 2006 |title=Glaxo unit buys Breathe Right maker |work=Trib Live |url=http://triblive.com/x/pittsburghtrib/business/s_474181.html |url-status=usurped |archive-url=https://web.archive.org/web/20130728161139if_/http://triblive.com/x/pittsburghtrib/business/s_474181.html |archive-date=28 July 2013}}</ref>

[[Chris Gent]], previously CEO of [[Vodafone]], was appointed chairman of the board in 2005.<ref>{{Cite web |date=28 October 2012 |title=Sir Christopher Gent to exit GlaxoSmithKline |url=https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9639020/Sir-Christopher-Gent-to-exit-GlaxoSmithKline.html |url-status=live |archive-url=https://web.archive.org/web/20230404113206/https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/9639020/Sir-Christopher-Gent-to-exit-GlaxoSmithKline.html |archive-date=4 April 2023 |access-date=10 September 2023 |website=The Telegraph |language=en}}</ref> GSK opened its first R&D centre in China in 2007, in Shanghai, initially focused on neurodegenerative diseases.<ref>{{cite news |url=https://www.reuters.com/article/idUSL2452000720070524 |title=Glaxo China R&D centre to target neurodegeneration |work=Reuters |date=24 May 2007 |author=Ben Hirschler |access-date=5 July 2021 |archive-date=11 August 2021 |archive-url=https://web.archive.org/web/20210811001312/https://www.reuters.com/article/idUSL2452000720070524 |url-status=live }}<br />
{{cite news |url=http://www.nature.com/news/2008/081029/full/4551168a.html |last=Cyranoski |first=David |title=Pharmaceutical futures: Made in China? |work=Nature |date=29 October 2008 |access-date=13 July 2012 |archive-date=10 June 2015 |archive-url=https://web.archive.org/web/20150610221842/http://www.nature.com/news/2008/081029/full/4551168a.html |url-status=live }}</ref> [[Andrew Witty]] became the chief executive officer in 2008.<ref>[http://www.gsk.com/about-us/corporate-executive-team.html "Corporate Executive Team"], GlaxoSmithKline. Retrieved 16 November 2013. {{webarchive |url=https://web.archive.org/web/20121014041607/http://www.gsk.com/about-us/corporate-executive-team.html |date=14 October 2012 }}</ref> Witty joined Glaxo in 1985, and had been president of GSK's Pharmaceuticals Europe since 2003.<ref>[https://www.youtube.com/watch?v=FHkj9dJ6aNE "Andrew Witty's journey from Graduate to GSK CEO"] {{Webarchive|url=https://web.archive.org/web/20170209112338/https://www.youtube.com/watch?v=FHkj9dJ6aNE |date=9 February 2017 }}, GlaxoSmithKline, 12 August 2008; [https://www.bloomberg.com/research/stocks/people/person.asp?personId=3027345&ticker=GSK "Andrew Philip Witty"], ''Bloomberg''.</ref>

In 2009, GSK acquired [[Stiefel Laboratories]], then the world's largest independent dermatology drug company, for {{US$|3.6 billion}}.<ref>{{cite news |last=Ruddick |first=Graham |url=https://www.telegraph.co.uk/finance/newsbysector/epic/gsk/5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html |archive-url=https://ghostarchive.org/archive/20220111/https://www.telegraph.co.uk/finance/newsbysector/epic/gsk/5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html |archive-date=11 January 2022 |url-access=subscription |url-status=live |title=GlaxoSmithKline buys Stiefel for $3.6bn |work=The Daily Telegraph |date=20 April 2009}}{{cbignore}}</ref> In November 2009, the FDA approved GSK's vaccine for 2009 H1N1 influenza protection, manufactured by the company's ID Biomedical Corp in Canada.<ref>{{cite web |date=16 November 2009 |title=FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190783.htm |url-status=usurped |archive-url=https://web.archive.org/web/20091119011901/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190783.htm |archive-date=19 November 2009 |publisher=[[Food and Drug Administration (United States)|US Food and Drug Administration (FDA)]]}}</ref> Also in November 2009, GSK formed a joint venture with [[Pfizer]] to create [[ViiV Healthcare]], which specializes in HIV research.<ref>{{cite web |last=Jack |first=Andrew |url=http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html |archive-url=https://ghostarchive.org/archive/20221210/http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html |archive-date=10 December 2022 |url-access=subscription |title=Companies / Pharmaceuticals – GSK and Pfizer to merge HIV portfolios |work=Financial Times |date=16 April 2009}}</ref> In 2010, the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for US$253m,<ref>{{Cite web |date=14 June 2010 |title=GSK Acquires Laboratorios Phoenix for 3m {{!}} InfoGrok |url=http://www.infogrok.com/index.php/pharma-companies/gsk-acquires-laboratorios-phoenix.html |url-status=dead |archive-url=https://web.archive.org/web/20100614180626/http://www.infogrok.com/index.php/pharma-companies/gsk-acquires-laboratorios-phoenix.html |archive-date=14 June 2010 |access-date=10 September 2023 |website=infogrok.com}}</ref> and the UK-based sports nutrition company Maxinutrition for £162{{nbsp}}million (US$256{{nbsp}}million).<ref>{{Cite news |last=Sandle |first=Paul |date=13 December 2010 |title=UPDATE 2-Glaxo buys protein-drinks firm Maxinutrition |work=Reuters |url=https://www.reuters.com/article/idUSLDE6BC0XO20101213 |url-status=live |archive-url=https://web.archive.org/web/20101216024711/https://www.reuters.com/article/idUSLDE6BC0XO20101213 |archive-date=16 December 2010}}</ref>